Note: Descriptions are shown in the official language in which they were submitted.
CA 02362794 2008-07-22
27855-94
1
Title: INHIBITORS OF SEPARASE, METHOD FOR IDENTIFYING THEM AND USES
The invention relates to compounds influencing mitosis and meiosis in
eukaryotic cells and methods for identifying such compounds. In particular,
the invention largely relates to the treatment and prevention of human
conditions by modulating sister chromatid segregation.
During the process of cell division, sister chromatids are pulled to opposite
halves of the cell by microtubules emanating from spindle poles at opposite
sides of the cell. One set of microtubules inter-digitates with others
emanating from the opposite pole. Their role is to keep (and drive) the two
poles apart. Meanwhile, a second set of microtubules attaches to
chromosomes via specialized structures called kinetochores and pulls them
towards the poles. Sister chromatids segregate away from each other
because their kinetochores attach to microtubules emanating from opposite
poles (Rieder et at., 1998). Chromosomes are not mere passengers during
this process. During metaphase, the tendency of microtubules to move
sisters apart is counteracted by cohesion holding sisters together.
Cohesion therefore generates the tension by which cells align sister
chromatids on the metaphase plate. Were sisters to separate before
spindle formation, it is difficult to imagine how cells could distinguish
sisters
from chromatids that were merely homologous. The sudden loss of
cohesion, rather than an increase in the exertion of microtubules, is thought
to trigger sister separation during anaphase (Miyazaki et at., 1994).
Cohesion also prevents chromosomes failing apart due to double strand
breaks and facilitates their repair using recombination.
To avoid missegregation of chromosomes, anaphase must only be initiated
after sister chromatids of each duplicated chromosome have attached to
opposite poles of the mitotic spindle. Microtubules are thought to "find"
kinetochores by a "search and capture" mechanism Which cannot be
completed simultaneously for all chromosomes (Hayden et al., 1990;
Merdes and De Mey, 1990). Cells therefore possess regulatory
mechanisms that delay sister chromatid separation until the last
chromosome has achieved bipolar attachment. The dissolution of sister
chromatid cohesion at the metaphase to anaphase transition is therefore a
highly regulated step during the eukaryotic cell cycle.
CA 02362794 2008-07-22
27855-94
2
Sister chromatid cohesion depends on a multi-subunit complex called
cohesin (Losoda et al., 1998), which contains at least four subunits: Smcl p,
Smc3p, Sccl p, and Scc3p, all of which are conserved between yeast and
humans. It is likely, but not yet proven, that cohesin is a key constituent of
the tether that holds sister chromatids together. The association between
cohesin and chromosomes has recently been shown to depend on the
Scc2 (Mis4) protein. Cohesion is established during DNA replication
(Uhlmann and Nasmyth, 1998). It has been recently shown that the Ecol
(Ctf7) protein is required for the establishment of cohesion during S phase
but unlike cohesin is not required to maintain cohesion during G2 and
M phases. In yeast, cohesin remains tightly associated with chromosomes
until metaphase; that is, it is present on chromosomes during their
alignment during metaphase. In animal cells, however, the bulk of cohesin
dissociates from chromosomes during prophase (Losada et al., 1998).. It is
unclear how much cohesin, if any, remains on chromosomes during
metaphase. The nature of the link that holds sister chromatids together
during metaphase in animal cells is therefore unclear. It could either involve
a small fraction of cohesin that remains associated with chromosomes or
some other protein complex.
In yeast, at least two of cohesin's subunits, Scclp and Scc3p, suddenly
disappear from chromosomes at precisely the point at which sister
chromatids separate (Michaelis et al., 1997). This has led to the notion that
a sudden change in the state of cohesin might trigger the onset of
anaphase, at least in yeast. In Drosophila, the meiS332 protein, which
binds to chromosomes during prometaphase, also disappears at the onset
of anaphase. MeiS332 is required for sister chromatid cohesion during
meiosis but not during mitosis (Moore et at., 1998; Kerrebrock et al., 1995).
MeiS332 is probably not a cohesin subunit nor is it apparent whether
homologous proteins exist in humans.
Both the dissociation of Sccl p from chromosomes and the separation of
sister chromatids are dependent on a specialized sister separating protein
(a separin; now mostly termed "separase" in the literature) called Esp1 p
(Ciosk et al., 1998). Separases homologous to Esp1 exist in the fission
yeast Schizosaccharomyces pombe, in the fungus Aspergillus nidulans, in
the nematode worm Caenorhabditis elegans, the fruit fly Drosophila
melanogaster, in the frog Xenopus laevis, in the plant
CA 02362794 2010-02-03
27855-94
3
Arabidopsis thaliana, and in man. This strongly
suggests that separases have a fundamental role in
chromosome segregation that is conserved between plants,
fungi, and animals. Espl is tightly bound by an inhibitory
protein called Pdslp whose destruction shortly before the
metaphase to anaphase transition is triggered by
ubiquitination mediated by the anaphase promoting complex
(APC) (Cohen-Fix et al., 1996). The APC is large multi-
subunit complex, most of whose subunits are conserved
between yeast and humans. Together with activator proteins
called Cdc20p and Cdhlp, it mediates the ubiquitination and
thereby destruction of many different cell cycle proteins,
including anaphase inhibitors like Pdsl and mitotic cyclins.
Pdsl destruction is mediated by a form of the APC bound by
the activator Cdc20. This form is called APCcdc2o. (For a
review, see Peters, 1998).
Proteins with similar properties to Pdsl have been
found in fission yeast (Cut2p), in Xenopus, and in humans
(Funabiki et al., 1996; Zou et al., 1999). The APC is
essential for sister chromatid separation in most if not all
eukaryotic organisms. In yeast, it is clear that its main
role in promoting sister separation is to destroy Pdsl,
which liberates Espl and allows it to destroy sister
chromatid cohesion, possibly by destroying the physical
links between sisters mediated by cohesin.
Summary of Invention
The present invention provides a method for
identifying a compound that can modulate sister chromatid
separation in plant or animal cells, said method comprising:
incubating a separase with a test compound in the presence
of a substrate containing separase cleavage site ExxR; and
determining whether proteolytic activity of said separase is
CA 02362794 2010-02-03
27855-94
3a
modulated; wherein the modulation of proteolytic activity of
said separase is indicative that said test compound can
modulate sister chromatid separation in plant or animal
cells.
It was an object of the invention to further
eluciate the mechanism of sister chromatid separation.
In particular, it was an object of the invention
to understand the mechanism by which Esplp mediates the
dissocation of Scclp from chromosomes in the budding yeast
in order to take advantage of this mechanism by using it as
a target in human therapy, in particular of cancer therapy,
and as a target in all other situations where modulation of
sister chromatid separation is therapeutically or otherwise
beneficial.
To solve the problem underlying the present
invention, the following approach was taken:
The observation that the dissociation of Scclp
from chromosomes at the onset of anaphase is dependent on
Espl suggested that Espl might either have a direct role in
this process or that Espl might be indirectly involved
CA 02362794 2001-08-14
WO 00/48627 PCT/EP00/01183
4
by initiating a process that leads to Sccl p's dissociation. It was found in
experiments of the present invention that Esp1 also prevents association of
Sccl p with chromosomes during G1 (see Example 1), which strongly
suggests that Esp1's role might be very direct. Sccl p is an unstable protein
which is rapidly destroyed following its dissociation from chromosomes at
the onset of anaphase and which must be re-synthesised during late G1
during the next cell cycle in order for cohesion to be established at the next
round of DNA replication (Michaelis et al., 1997) It was found that Sccl p
synthesised during G2 is also capable of binding to yeast chromosomes
but that it fails to produce cohesion under these circumstances (Uhlmann
and Nasmyth, 1998). However, it was noted that Sccl p synthesised during
early G1 binds to chromosomes poorly, if at all. As shown in Figure 1,
inactivation of Esp1 permits the efficient association between Sccl p and
chromosomes during early G1. The implication is that Esp1 not only
triggers Sccl p's dissocation from chromosomes at the onset of anaphase
but also prevents Sccl p's stable association with chromosomes during the
subsequent G1 period. This strongly suggests that Esp1 has a fairly direct
role in controlling the association between Sccl p and chromosomes.
Starting from this finding, an assay was established by which Esp1 activity
could be measured in vitro. A crude preparation of yeast chromatin isolated
from cells arrested in a metaphase-like state by nocodazole, was incubated
with a soluble extract prepared from cells over-producing Esp1 from the
GAL promoter (Figure 2). To detect Sccl p, cells were used whose Sccl
protein was tagged at its C-terminus with multiple HA or Myc epitopes,
which can readily be detected with monoclonal antibodies. About 70% of
the total Sccl p in nocodazole blocked cells is tightly associated with
chromatin and is therefore present in the chromatin fraction that was used.
Most of the Sccl p remains tightly associated with chromatin following
incubation with an extract prepared from espl-1 mutant cells but most
3o disappears from the chromatin fraction upon incubation with extracts
containing high levels of wild type Esp1 protein. Somewhat surprisingly, the
Sccl p protein induced to dissociate from chromatin by Esp1 appeared in
the "soluble" supernatant fraction as a cleaved product. The C-terminal
fragments of this cleavage were detected by using as a substrate a C-
terminally tagged Sccl protein and N-terminal fragments using as substrate
an N-terminally tagged Sccl protein. The sizes of these cleavage products
CA 02362794 2001-08-14
WO 00/48627 PCT/EP00/01183
suggested that Espl induces one or more specific cleavages of Sccl p
within a 10 kd interval. This Espl-dependent cleavage was inhibited by the
addition of reticulate lysate that had translated Pdsl but not by an
otherwise identical lysate that had translated an unrelated control protein.
5 The Espl activity detected by the cleavage assay is therefore inhibited by
Pds1, which demonstrates directly, for the first time, that Pdsl is indeed an
inhibitor of Espl p.
To address whether Espl induced cleavage of Sccl p also occurs in vivo at
the onset of anaphase, a yeast strain was constructed in which expression
of the APC activator Cdc20p is under control of the galactose inducible
GAL 1-10 promoter. The strain also expressed an Sccl protein tagged at its
C-terminus with multiple HA or myc epitopes. Cells from this strain were
arrested in metaphase by incubation in galactose free medium and then
induced to embark on anaphase highly synchronously by the addition of
galactose. Figure 3 shows that sister chromatids separate in most cells
within 15 minutes and that Sccl p dissociates from chromosomes with
similar if not identical kinetics. A low level of an Sccl cleavage product was
detected that is identical to that seen in vitro in cycling cells but none in
cells arrested in metaphase. The cleavage product suddenly appeared
upon induction with galactose with kinetics that were similar if not identical
to the separation of sister chromatids and dissocation of Sccl p from
chromosomes. To establish whether this in vivo cleavage was dependent
on Espl activity the extent of Sccl p cleavage in wild type and espl-1
mutants when released from cdc20 arrest at 35.5 C was compared (the
restrictive temperature for esp1-1). The extent of Sccl p cleavage was
greatly reduced in the espl-1 mutant. It was concluded that Espl promotes
the cleavage of Sccl p and its dissociation from chromosomes both in vivo
and in vitro.
To address whether cleavage of Sccl mediated by Espl is important either
for sister chromatid separation or for Sccl p's dissociation from
chromosomes, the cleavage site was mapped in order that it could then be
mutated. An epitope tagged Sccl p protein from cells that had been
stimulated to undergo anaphase by induction of Cdc20 expression was
immunoprecipiated and the immunoprecipitated proteins were separated
on SDS page. A short stretch of N-terminal amino acid sequence from the
CA 02362794 2001-08-14
WO 00/48627 PCT/EPOO/01183
6
C-terminal cleavage fragment was then determined by Edman degradation.
This showed that cleavage in vivo had occured between a pair of arginines
at positions 268 and 269. The N-terminal of these arginine residues was
then mutated to aspartic acid and an HA tagged version then was
expressed from the GAL 1-10 promoter in yeast cells whose endogenous
Sccl protein was myc tagged. Galactose induced expression of this single
mutant protein had little effect on cell proliferation. To establish whether
the
mutation had indeed abolished cleavage, chromatin from cells expressing
the mutant protein was isolated and used as a substrate in the Esp1 assay.
1o This showed that cleavage at site 268 was indeed eliminated by the
aspartic acid mutation. However, the mutated protein was still cleaved in an
Esp1-dependent manner. The C-terminal cleavage product from the mutant
protein was about 10 kDa longer than that from wild type. The interpretation
of these results is that Sccl p is actually cleaved at two sites approximately
10 kDa apart. Cleavage at the more C-terminal site is highly efficient, which
is why C-terminal tagged proteins cleaved only at the more N-terminal site
were rarely detected.
To identify the second cleavage site, sequences within Sccl p which are
similar in sequence to those surrounding the known C-terminal cleavage
site were looked for. A 5 out of 7 amino acid match at position 180 found.
Furthermore, the distance between this potential site and the known
cleavage site is consistent with the greater length of the cleavage product
generated in vitro from protein whose C-terminal site (R268) had been
mutated. The matching sequence also contained a pair of arginines and
therefore the more N-terminal arginine was mutated to aspartic acid. Next
the effect of expressing HA tagged versions of wild type Sccl p, both single
mutant proteins, and the double mutant protein from the GAL1 promoter in
yeast was compared. As a host for these studies a strain was used whose
endogenous Sccl p was myc tagged. Neither wild type nor either single
mutant blocked cell proliferation but expression of the double mutant
protein was lethal. Chromatin from cells transiently expressing these
proteins was prepared and it was shown that HA tagged double mutant
protein was no longer cleaved when incubated in Esp1-containing extracts
while the myc tagged wild type protein was efficiently cleaved.
CA 02362794 2001-08-14
WO 00/48627 PCT/EP00/01183
7
To investigate why cells expressing a non-cleavable Sccl p protein (the
R180D R268D double mutant) cannot proliferate, centrifugal elutriation was
used to isolate G1 cells from a culture growing in the absence of galactose
which were then incubated in the presence and absence of galactose
(Fig. 4). In order to minimize the duration of mutant protein expression, the
cells grown in the presence of galactose were transferred to glucose
containing medium after most cells had replicated their DNA (at 135 min).
In the absence of galactose, sister separation and dissociation from
chromosomes of endogenous myc tagged Sccl p occured simultaneously,
1o approximately 60 min after DNA replication. Transient expression of double
mutant protein greatly reduced sister chromatid separation (Fig. 4b) but did
not affect dissociation of endogenous myc tagged wild type protein (Fig. 4c
and d). Furthermore, the mutant protein remained tightly associated with
chromosomes long after the endogenous wild type protein had
disappeared. Expression of the mutant protein did not greatly delay cell
cycle progression and most cells underwent cytokinesis, producing progeny
with low (0-0.5C) amounts of DNA and cells with less than a 2C DNA
content (Fig. 4a). The dissociation from chromosomes of wild type protein
on schedule shows that the lack of sister separation in cells expressing
2o non-cleavable Sccl p is not due to a lack of Esp1 activity. Collectively,
the
data obtained imply that cleavage of Sccl p at one of two sites is necessary
both for sister chromatid separation and for dissociation of Sccl p from
chromosomes.
From the obtained results it can be concluded that cohesin directly
mediates the link between sister chromatids that is established during DNA
replication and is maintained until metaphase. It can be further concluded
that Esp1's activation by proteolysis of Pdsl (and by as yet to be identified
other mechanisms) generates an activity inside cells that cleaves the
Sccl p subunit of cohesin and that this event both destroys sister chromatid
cohesion and causes Scclp and possibly other cohesin subunits to
dissociate from chromosomes.
From the above results it is clear that sister chromatid separation depends
on cleavage of chromosome-bound Sccl by an Esp1-dependent proteolytic
activity that appears in cells at the onset of anaphase. It was next asked
whether Sccl as an isolated protein (rather than in the chromosomal
CA 02362794 2008-07-22
27855-94
8
context) can also serve as a substrate for the Esp1-dependent cleavage
reaction. Fig. 5 describes the purification of recombinant Sccl after over-
expression in insect cells infected with a recombinant baculovirus. Sccl
was purified either from an asynchronously growing population of infected
insect cells (Fig. 5a, lanes 1-4) or from infected insect cells that had been
treated with the phosphatase inhibitor okadaic acid. Treatment with okadaic
acid induces a metaphase-like state within the insect cells as a
consequence of which Sccl is obtained in a mitotically phosphorylated
form (Fig. 5a, lane 5). Sccl in yeast appears also phosphorylated in a
1o mitosis specific manner. These Sccl fractions, that were more than 9000
pure as judged by SDS-PAGE followed by staining of the gel with
Coomassie brilliant blue, were then used in the Sccl cleavage assay as
described above (Fig. 5b). Both unphosphorylated and phosphorylated
purified Sccl were cleaved in an Esp1-dependent manner in vitro,
however, the efficiency of cleavage was much greater when Sect was in
the mitotically phosphorylated state. From this experiment it was concluded
that isolated Sccl which is neither part of the cohesin compex nor bound to
chromosomes is a substrate for cleavage by Esp1, at least if it is in its
mitotically phosphorylated state.
It was then addressed, whether Espl is itself the protease that cleaves
Sccl. Inhibitor studies showed that the in vitro cleavage activity could be
inhibited by N-ethyl maleimide an inhibitor specific for proteases using a
catalytic cysteine residue. Inspection of the amino acid sequence within the
evolutionary conserved C-terminal half of Espl revealed that exactly one
cysteine and one histidine residue are conserved in all known separase
homologues. These two residues might therefore form the catalytic dyad of
a new subclass of cysteine protease. When the amino acid sequences
surrounding the potential catalytic dyad were further analysed, it was found
that both the cysteine and the histidine residues are preceded by a
sequence stretch predicted to form a hydrophobic beta sheet. Furthermore,
the histidine is invariably flanked by two glycine residues and the cysteine
is preceded by a glycine providing the possibility for a tight turns before or
after the catalytic residues. This arrangment of histidine and a cysteine
catalytic dyad residues fixed at the ends of two neighbouring strands of
hydrophobic beta sheet is used in the caspase family of proteases and it
seems likely that the same arrangment is used in separases like Esp1.
CA 02362794 2008-07-22
27855-94
9
To provide evidence that Esp1 indeed uses these two amino acid residues
histidine (amino acid position 1505) and cysteine (position 1531) as a
catalytic dyad for cleaving Sccl,either of these amino acids were mutated
to alanine. Both mutations completely abolished the proteolytic activity in
yeast extracts after overproduction of the proteins (Fig. 6). Wild type Esp1
overexpressed to a similar level caused complete cleavage of the Sccl .
substrate. It was concluded that histidine 1505 and cystein 1531 most likely
form the catalytic dyad that provides Esp1 with its proteolytic activity to
cleave Sccl.
1o Together these results provide compelling evidence that a proteolytic
reaction in which Esp1 separase cleaves the cohesin Sccl is the initiating
event for sister chromatid separation at the metaphase to anaphase
transition in mitosis in S. cerevisiae.
It was next asked whether the same proteolytic mechanism might act to
13 initiate chromosome separation during the two meiotic nuclear divisions.
During premeiotic DNA replication a Sccl-homolog, called Rec8, replaces
Sccl in the cohesin complex (Klein et al., 1999). Rec8, like Sccl, contains
two separase recognition sites, which suggests that Espl/separase might
cleave Rec8 during meiosis to initiate meiotic chromosome separation. To
20 test this, both separase cleavage sites within Rec8 were mutated to produce
a non-cleavable version of this protein. Expression of the non-cleavable
Rec8 during meiosis led to a block of the first meiotic nuclear division (Fig.
7A), indicating that cleavage of Rec8 is necessary to separate sister
chromatid arms in the first meiotic division. When meiosis was followed in a
25 yeast strain containing the espl-2 mutation, a temperature sensitive
mutation in the ESPI gene, a temperature dependent block of the first
meiotic nuclear division was likewise observed (Fig. 7B). It was concluded
that separase cleaves the cohesin Rec8 during the meiotic nuclear divisions
as it cleaves Sccl during the mitotic division.
30 The sequences of human homologs of budding yeast Espl, Pdsl and Sccl
already exist in public databases. The human homologs of Espl and Pds1
are referred to as separin or separase (Nagase et al., 1996; protein sequence:
NCBI
Acc. No. BAA11482; DNA sequence: NCBI Acc. No. D79987) and securin
(Zou et al., 1999, Dominguez et al., 1998) respectively, and the human
35 homolog of Sccl as SCC1 (McKay et al., 1996; DNA sequence: NCBI Acc.
CA 02362794 2001-08-14
WO 00/48627 PCT/EP00/01183
No. X98294; protein sequence: NCBI Acc. No. CAA 66940). In animal cells
it has been shown that the majority of SCC1 dissociates from chromatin in
prophase long before sister chromatids are separated in anaphase, and no
cleavage of SCC1 has been observed during this process (Losada et al.,
5 1999).
Another object of the experiments of the present invention was to test
whether some SCC1 remains bound to condensed chromosomes and
maintains sister chromatid cohesion until the initiation of anaphase, and to
analyze whether the chromosome-bound form of SCC1 was subject to
10 proteolytic cleavage at the onset of anaphase.
To answer these questions, the following approach was taken: Human
HeLa cells were enriched in interphase by logarithmic growth and in
metaphase by treatment with nocodazole, and crude chromatin and
supernatant fractions were generated by differential centrifugation and
analyzed for the presence of SCC1 by quantitative immunoblotting (Fig. 8).
The amount of the total cellular SCC1 associated with chromatin was
reduced from 56 % in logarithmically growing cells to 13 % in cells arrested
in metaphase. It was concluded that most but not all SCC1 dissociates
from chromatin before metaphase, consistent with the possibility that SCC1
may be required to maintain sister chromatid cohesion until the onset of
anaphase.
To address whether the form of SCC1 that is associated with
chromosomes in metaphase is cleaved in anaphase, HeLa cells were
arrested at the onset of S-phase by double-thymidine treatment and were
synchronously released into the cell cycle. Progression through the cell
cycle was monitored at different time points after the release by analysis of
the DNA content with fluorescence activated cell sorting (FACS) and by
analyzing total cell lysates in immunoblot experiments. Figure 9 shows that
a putative SCC1 cleavage product corresponding to 100 kDa was
recognized by antibodies specific for the C-terminus of SCC1. Importantly,
this band appeared specifically when the HeLa cells went through
anaphase, as judged by FACS analysis and the disappearance of securin,
cyclin B and CDC20, proteins that are known to be degraded specifically in
anaphase.
CA 02362794 2008-07-22
27855-94
11
To confirm that the anaphase-specific 100 kDa band is a cleavage prodcut
of SCC1 and not a non-specific crossreaction of the antibodies used, the
following two experiments were performed: First, antibodies specific for the
N-terminus of SCC1 were raised and used to analyze the HeLa cells cycle
fractions by immunoblotting. A band of 25 kDa was recognized specifically
in anaphase (Fig. 9), consistent with the interpretation that SCC1 is cleaved
into an C-terminal 100 kDa and a N-terminal 25 kDa fragment. Second, a
HeLa cell line stably expressing mouse SCC1 fused to a myc epitope tag at
the C-terminus (SCCI-myc) was analyzed by cell synchronization as
above. The amount of SCC1-myc expressed in these cells is less than 10%
of endogenous SCC1 and the ectopic protein is entirely incorporated into
14S cohesin complexes (Fig. 10A). In synchronized cells, antibodies to the
myc epitope recognize a band of the expected size (120 kDa) that appears
in anaphase with similar kinetics as the 100 and 25 kDa bands recognized
by SCC1 antibodies, demonstrating unambiguously that mammalian SCC1
is cleaved in anaphase (Fig. 108), In addition, these immunoblots revealed
a second anaphase-specific fragment of SCC1-myc, suggesting that SCCI
cleavage occurs at at least two sites (Fig. 10B bottom panel).
Biochemical experiments in Xenopus have shown that the initiation of
anaphase depends on proteolysis of securin mediated by APCCDC20 (Zou
et al., 1999). Like budding yeast Pdsl and Esp1, securin and separase form
a complex, consistent with the hypothesis that APCCDC20-dependent
securin proteolysis activates separase. To address whether SCC1 cleavage
depends on activation of APCCDC20 and subsequent securin proteolysis
HeLa cells were synchronized by double-thymidine treatment and released
into the cell cycle in the presence of nocodazole. Nocodazole is a drug
known to indirectly cause the inhibition of APCCDC20 and thereby to arrest
cells in metaphase (reviewed by Peters, 1998). Specific antibodies to
human securin were raised and it was shown that securin was not
degraded under these conditions (Fig. 11). Importantly, no, cleavage of
SCC1 could be observed in the presence of nocodazole. The effect of the
drug was reversible because release of nocodazole arrested cells into
anaphase correlated with degradation of securin and formation of the
SCC1 cleavage products (Fig. 12). These results suggest that SCC1
cleavage depends on activation of APCCDC20 and are consistent with the
CA 02362794 2008-07-22
27855-94
12
hypothesis that securin degradation and subsequent separase activation are
required for SCCI cleavage.
To analyze the regulation of SCC1 cleavage further and as a first step to
develop a screening assay for inhibitors of this reaction an in vitro assay
utilizing SCC1-myc and cell cycle extracts prepared from Xenopus eggs
was established. These extracts can. be manipulated to represent either a
stable interphase state in which APCCDC20 is inactive or a stable mitotic
state in which APCCDC20 is active and in which sister chromatid
separation can occur in vitro (Murray et al., 1991) When chromatin isolated
from HeLa cells stably expressing SCCI-myc was incubated in Xenopus
extracts, cleavage of SCC1 at two distinct sites could be detected in the
mitotic but not in the interphase extract, further confirming that APCCDC20
activity is required for this event (Fig. 13). In SDS-PAGE, the cleavage
products formed in vitro comigrated with the cleavage products formed in
vivo, suggesting that cleavage in the extract occurs at physiologically
relevant sites. Importantly, some SCC1 cleavage was also observed when
chromatin-free supernatant fractions from HeLa cells were mixed with
mitotic extracts (Fig. 13). This demonstrates that soluble human SCC1 can
be a substrate for cleavage and thus makes the development of a
simplified chromatin-free cleavage assay for drug screening purposes
feasible.
To map the more N-terminal cleavage site in SCC1 a series of N- and C-
terminal deletion mutants was generated and the electrophoretic mobility of
the truncated proteins was compared to the mobility of the N- and C-
terminal cleavage products formed in vivo (Fig. 14). cDNAs encoding
deletion mutants were generated by polymerase chain reactions (PCR) and
recombinant S35-labeled! proteins were generated from the PCR products
by in vitro transcription and translation. This analysis indicated that SCC1
is
cleaved between amino acid residues 169 and 183. This site contains the
sequence motif ExxR172 which is conserved in many SCC1 homologs in
different species and is also found in both N-terminal cleavage sites of
budding yeast Sccl. Preliminary results using the same mapping strategy
indicate that the C-terminal cleavage site in SCC1 is located around amino
acid residue 450 where the motif ExxR is found again.
CA 02362794 2008-07-22
27855-94
13
Based on the results of the experiments of the present invention it can be
concluded that separase-dependent SCCI cleavage is a mechanism that is
conserved from budding yeast to humans and that the same mechanism
most likely exists in all eukaryotic organisms. The findings obtained in
experiments performed with budding yeast are therefore also valid in higher
eukaryotic organisms, in particular in man.
The interpretation of the data obtained in the experiments of the present
invention further provides evidence that Espl/separase itself is the protease
responsible for the cleavage of Sccl p/SCC1.
From the results obtained in the experiments of the invention, it may, inter
alia, be concluded that Sccl p/SCC1 is the only subunit of the cohesion
comples cleaved by Espl/separase.This does, however, not exclude the
possibility that other types of proteins, for example, other cohesion proteins
or proteins which regulate mitotic spindles, might also be targets/substrates
of separase. One way of addressing this question is to make a version of
Sccl p that has one cleavage site replaced with a site for a foreign protease
(with the other cleavage site removed). An example for a convenient
protease to use is TEV protease (Daugherty et al., 1989), which has a very
specific cleavage site (Glu-Asn-Leu-Tyr-Phe-Gln-Gly). A strain can be
constructed that contains: the SCCI gene containing a TEV protease
cleavage site, a chromosomal cdc20-3 mutation, and the TEV protease
gene under GALS-10 inducible control. In the presence of galactose at the
restrictive temperature (when cdc20-3 cells are arrested in metaphase due
to their failure to destroy Pds1), the effect of the artificial cleavage of
Sccl p
on its removal from chromosomes can be assayed (as measured by its
presence in sedimented chromosomal DNA fractions). Whether or not this
is sufficient for sister chromatid separation can also be examined
microscopically, using the CenV-GFP system (Ciosk et at, 1998; see
Example 3). These experiments allow to determine whether the rest of
mitosis can proceed under these conditions in the absence of separase
function (note that separase is inactive in cdc20-3 mutants at the restrictive
temperature due to the presence of its inhibitor Pdsl). If the foreign
protease triggers Sccl p's dissociation from chromatids under these
circumstances and sister chromatids segregate to opposite poles of the
yeast cell, it can be concluded that cleavage of Sccl is the sole function of
CA 02362794 2008-07-22
27855-94
14
separase needed for sister chromatid segregation.. If however, sister
chromatids fail to segregate to opposite poles of the cell despite the variant
Scc1 p having been removed from chromatin, then it is concluded that
separase has one or more functions besides cleavage of Sccl p. A clue as to
these functions can be obtained from the phenotype of these cells and this
can be used to identify other potential substrates for Espl.
The findings of the experiments of the present invention have shed the first
key insight into the molecular mechanism by which eukaryotic cells
separate sister chromatids. In view of the published literature, which
1 o contains no hints as to the mechanism by which sister chromatids are
separated, the finding that separases act by conferring a proteolytic activity
is
highly surprising.
The identification of Esp1/separase as the protease responsible for
Scc1/SCCI cleavage and the identification of potential co-factors, is the
prerequisite for designing assay methods Brat allow for finding compounds
interfering with sister chromatid separation, which is the basis for novel
therapeutic approaches.
In a first aspect, the invention relates to a method for identifying
compounds that have the ability of modulating sister chromatid separation
in plant or animal cells, characterized in that a protease with separase-like
cysteine endopeptidase activity is incubated, in the presence of the
substrate(s) for its proteolytic activity and optionally its co-factor(s),
with test
compounds and that the modulating effect of the test compounds on the
proteolytic activity of the cysteine endopeptidase is determined.
By providing a method to identify compounds which exert their effect by
directly modulating, in particular by inhibiting separase's proteolytic
activity,
i.e. by being protease inhibitors specific for separase, the present invention
provides means for interfering with the mechanism of sister chromatid
separation and thus a novel approach for inhibiting the proliferation of
rapidly dividing animal cells, in particular tumor cells.
in the following, if not otherwise stated, the term "separase" is used as a
synonym for any cysteine endopeptidase with separase-like activity, including
the yeast homolog Esp1. Similarly, the term "SCC1" is not limited to the
CA 02362794 2008-07-22
27855-94
human separase substrate, but is intended to encompass any homologous
substrate of the cohesin-type.
In a first embodiment, for small scale applications, the assay of the type as
described in Example 2 for the yeast components can be used to identify
5 compounds that inhibit separase activity. Given the existence of Espl
homologues in man, i.e. separase, it can be concluded that the separase
activity plays an important role in triggering anaphase onset also in
humans. Therefore, a separase-dependent cleavage assay using human
separase and SCCI instead of yeast components can be established using
1o the principles outlined in the experiments for yeast components. Such an
assay comprises, as its essential. features, incubating a crude preparation
of chromatin with a preparation containing a separase activity and
determining SCC1 cleavage products in the presence or absence of a test
substance.
15 In general, when setting up a screening assay, it may be useful to first
perform it with yeast constituents as assay components and subsequently
further develop it stepwise using the protease and/or substrate from
intermediate organisms, e.g. from S. pombe or Xenopus laevis, and finally
equivalent human substrates. For example, the S. pombe homologue of
Sccl (called Rad2l) contains two sequences which are similar to the two
known cleavage sites in Sccl, and Rad2l derived sequences may
therefore be used to generate a substrate for S. pombe Esp1 (called Cut1).
This process of advancing to higher organisms can be applied stepwise
until a human system is attained. The cleavage site of any new substrate
for human separase can be determined by purifying the cleavage product
and determining the N-terminal sequences by Edman degradation as
described above.
In a preferred embodiment, the method of the invention is performed on a
high-throughput scale. For this embodiment the major assay components,
in particular separase, are employed in recombinant form.
Depending on the desired application of the separase-inhibitor to be
identified, the assay components employed may vary in terms of the
species that they are derived from. In view of therapeutical applications in
animals or humans, the assay components are preferably of mammalian or
CA 02362794 2008-07-22
27855-94
16
human origin, in case of intended agricultural applications, the assay
components are derived from plants.
Separase can be produced recombinantly according to standard methods,
e.g in yeast or insect cells or in other suitable host cells, based on the
sequence information in the literature or in data bases. The obtained
protein can be purified by conventional biochemical fractionation from yeast
cells over-producing separin or by tagging the over-produced protein with
polypeptide sequences which have a special affinity for a defined ligand
(affinity purification). For example, separase can be purified on nickel-
agarose columns if it has been tagged with multiple histidine residues,
whereas it can be purified on glutathione-agarose columns if it has been
tagged with GST. Such affinity purification involves the cleavage of separase
from its tag using site specific proteases or self cleaving inteins. The thus
obtained recombinant protein can then be used to determine, according to
known methods for assaying proteolytic activity, whether separase alone is
capable of cleaving Sccl p or peptide substrates derived from it. In case
that separase is alone capable of cleaving a SCC1 or a SM -derived
peptide, an assay based on, preferably recombinant, separase as the
protease and its substrate SCC1 can easily be adapted to a high
throughput format by methods that are standard for other defined
proteases, as described below.
The protease substrates useful in the assay may be those equivalent to or
mimicking the naturally occuring substrates, e.g. crude chromatin
preparations, SCC1, preferably recombinantly produced, or an SCCI
peptide that contains the proteolytic cleavage site.
Based on information about the sequence specificity of the separase
proteolytic cleavage site in yeast and in man, other potential substrates for
the protease can be found in other organisms, including humans, which
also allows for the design of peptides derived from these substrates, which
are useful as substrates in the screening assay of the invention.
In a preferred embodiment, the substrate is a peptide containing the
cleavage site of the naturally occuring substrate. The sequence specificity
of the proteolytic cleavage can be determined by testing a variety of
different peptides. The peptide may be of natural origin, i.e. derived from
CA 02362794 2008-07-22
27855-94
17
the natural SCC1, or a variant. An example for a natural peptide ist the
human SCC1 peptide as set forth SEQ:ID:NO:1, or a fragment thereof that
contains the separase cleavage site. Variants can be generated either by
synthesising variant peptides or by mutating DNA sequences from genes
encoding cohesion proteins. More specifically, other substrates for separase
can be identified by searching for small DNA fragments from the yeast
genome or an oligonucleotide library that can replace the normal Scc1
cleavage sites. Oligonucleotides may be inserted into a SCC1 gene
(lacking both natural cleavage sites) under control of the GAL promoter on
1o centromeric plamid. Yeast cells may be transformed with a library of such
constructs and only plasmids whose modified Sccl protein can be cleaved
by the separase activity will permit growth in the presence of galactose. The
peptides encoded by the positive constructs are useful as substrates for
separase in the screeing assay of the invention.
With regard to the substrate, e.g. the SCC1 protein or a peptide fragment
thereof, care needs to be taken that the substrate is efficiently cleaved. It
has to be considered, in particular when using the yeast homolog of SCC1,
that efficient cleavage appears to occur only when the substrate is in its
phosphorylated state, as it is present in mitosis. Therefore, when designing
a peptide substrate or when producing SCC1 recombinantly, it has to be
tested whether the substrate is efficiently cleaved by separase. In case of
the
recombinant protein, it can be obtained in its phosphorylated form by
producing it in infected insect cells that are treated with a phosphatase
inhibitor, e.g. okadaic acid. This method is exemplified, for the yeast Sccl
protein, in Example 5 (method section e) and can, if necessary for other
SCC1 molecules, be adapted for these molecules.
In the case that separase does not act by itself, but in cooperation with co-
factors, instead of incubating SCCI (or peptide substrates) with separase
alone, they can be incubated with a mixture of separase and its co-factors.
All components can be produced and purified according to standard
methods as outlined above for separase.
For the high throughput format, the screening methods of the invention to
identify separase inhibitors, are carried out according to assay methods
known in the art for identifying protease inhibitors. Such assays are based
on the detection of the cleavage products of the substrate. To achieve this,
CA 02362794 2008-07-22
27855-94
18
an SCC1 peptide or protein substrate that contains cleavage sites for the
separase protease is derivatized with a detectable label, e.g a radioactive or
a fluorescent label. Upon cleavage of the substrate by the protease, the
cleavage product can be measured. If a test substance is an inhibitor of the
protease, there will be, depending on the detection system and depending
on whether the test substance has an inhibiting or an activating effect, a
decrease or an increase in the detectable signal.
In the high-throughput format, compounds with a modulationg effect on
separase or a separase-like cysteine endopeptidase can be identified by
1o screening test substances from compound libraries according to known
assay principles, e.g. in an automated system on microtiter plates.
Recently, various assay methods for identifying protease inhibitors have
been described that are amenable to automation in a high-throughput
format, e.g. the radiometric method described by Cerretani et at., 1999, for
Hepatitis C virus NS3 protease, the method based on fluorescence
quenching described by Ambrose et at., 1998, or by Taliani et at., 1996, the
microliter colorimetric assay fot the HIV-1 protease described by Stebbins
and Debouck, 1997, the fluorescence polarization assay described by
Levine et at., 1997 (reviewed by Jolley, 1996), the method using
immobilized peptide substrates described by Singh et at., 1996, the assay
used for studying the inhibition of cathepsin G, using biotinylated and
cysteine-modified peptides described by Brown et at., 1994. A further
example for a suitable assay is based on the phenomenonon of
fluorescence resonance energy transfer (FRET), as described by
Gershkovich et at., 1996 or by Matayoshi et al., 1990. Additional examples
for assays that may be used in the present invention for a high-throughput
screening method to identify inhibitors of separase activity were described by
Gray et al., 1994, Murray et at., 1993, Sarubbi et at., 1991.
Fluorescent or radioactive labels and the other reagents for carrying out the
enzymatic reaction on a high-throughput scale are commercially available
and can be employed according to supplier's instructions (e.g. Molecular
Probes, Wallac). The specific assay design depends on various
parameters, e.g. on the size of the substrate used. In the the case of using
a short peptide, the fluorescence quenching or the fluorescence resonance.
energy transfer methods are examples for suitable assay technologies.
CA 02362794 2008-07-22
27855-94
19
The fluorescence quenching (Resonance Energy Transfer RET") assay
relies on synthetic substrates which are capable of direct, continuous signal
generation that is proportional to the extent of substrate hydrolysis. The
substrate peptide carries a fluorescent donor near one end and an
acceptor near the other end. The fluorescence of the substrate is initially
quenched by intramolecular RET between donor and acceptor. Upon
cleavage of the substrate by the protease the cleavage products are
released from RET quenching and the a fluorescence proportional to the
amount of cleaved substrate can be detected.
1o An assay of this type may be carried out as follows: the solution of the
labeled substrate (e.g. the peptide labeled with
4-[[4'-(dimethylamino)phenyl]azo]benzoic acid (DABCYL) at the one end
and with 5-[(2'-aminoethyl)amino]naphtalenesulfonic acid (EDANS) at the
other end or labeled with benzyloxycarbonyl at the one end and with 4-
aminomethylcoumarin at the other end) in assay buffer is pipetted into each
well of black 96-well microtiter plates. After addition of the test substances
in the defined concentration, the separase solution is added to the wells.
After incubation under conditions and for a period of time sufficient for the
proteolytic cleavage reaction, e.g. for 1 hour at room temperature, the
fluorescence is measured in a fluorometer at the excitation wavelength,
e.g. at 340 nm, and at the emission wavelength, e.g. at 485 nm.
In the case of using the FRET assay, the following commercially availabe
labeling pairs are suitable for the method of the invention: Europium (Eu)
and Allophycocyanin (APC), Eu and Cy5, Eu and PE (Wallac, Turku,
Finland).
The compounds identified in the above methods, which are also subject of
the invention, have the ability to interfere with sister chromatid separation
by modulating the proteolytic activity of a separase-like cysteine
endopeptidase.
In a preferred embodiment, the compounds of the invention are inhibitors of
a separase-like cysteine endopeptidase.
Preferably, the compounds are specific inhibitors of separase.
CA 02362794 2008-07-22
27855-94
The present invention also relates to compounds which act as inhibitors of
separasefor use in human therapy, in particular cancer therapy.
In a further aspect, the invention relates to a pharmaceutical composition
which contains, as the active ingredient, one or more compounds which
5 interfere with or modulate sister chromatid separation by inhibiting the
proteolytic activity of separase.
The present invention also encompasses inhibitors of any protease that is
recognized to be a separase-like protease because of its sequence similarity
to separases; i.e all proteases in which amino acid sequences surrounding
10 the catalytic dyad are more similar to separases, than to any class of
protease
currently known.
In a preferred embodiment, the invention comprises pharmaceutically
active compounds and their use in therapy, which are small chemical
molecules that have been identified as separase inhibitors in the screening
15 method of the invention.
Alternatively, the separase inhibitors may be biological molecules, e.g.
peptides or peptide-derived molecules like pepidomimetics.
Proteases from the caspase family, to which :separase is likely to belong,
have been shown to be good targets for irreversible binding and inhibition
20 by peptide derived inhibitors (Nicholson et al., 1995; Faleiro et al.,
1997). In
principle, the approach described for the caspase inhibitors, which act as
"recognition site peptides" by being modified to contain an aldehyde,
halogenomethyl or acyloxymethyl group at the cleavage position, can be
adapted to irreversibly bind to and inhibit the active site cysteine residue
in
separase. Inhibitory peptide derivatives of this type can be the starting
point
for rational inhibitor design, e. g. derivatives of the peptide spanning the
amino acid sequence at the protease recognition site in SCC1 or another
separase substrate. An example for a peptide to be considered for such
design is the peptide derived from human SCC1,
MDDREIMREGSAFEDDDM (SEQ:ID:NO:1), which contains the separase
cleavage site, or a mutation or fragment thereof. The inhibitor design can
also be aided by obtaining structural information about the catalytic domain
of Espl using. x-ray crystallography. Initially the structure of the Esp1
CA 02362794 2008-07-22
27855-94
21
catalytic domain can also be modelled onto the already known structures of
two members of the caspase family of proteases.
The efficacy of compounds identified as separase inhibitors can be tested for
in vivo efficacy either on yeast cells or in mammalian cells. Effective
compounds should block (or at least in some way interfere with) sister
chromatid separation, which can be measured, e.g. by using CenV-GFP in
yeast, as described by Ciosk et at., 1998, or standard cytological
techniques in mammalian cells. Effective compounds should be either
cytostatic or cytotoxic. Substances whose potential for therapeutic use has
lo been confirmed in such secondary screen can be further tested for their
effect on tumor cells. To test the inhibition of tumor cell proliferation,
primary human tumor cells are incubated with the compound identified in
the screen and the inhibition of tumor cell proliferation is tested by
conventional methods, e.g. bromo-desoxy-uridine or 3H incorporation.
Compounds that exhibit an anti-proliferative effect in these assays may be
further tested in tumor animal models and used for the therapy of tumors.
Toxicity and therapeutic efficacy of the compounds identified as drug
candidates by the method of the invention can be determined by standard
pharmaceutical procedures, which include conducting cell culture and
animal experiments to determine the IC50, LD50, the ED50. The data
obtained are used for determining the human dose range, which will also
depend on the dosage form (tablets, capsules, aerosol sprays, ampules,
etc.) and the administration route (oral, buccal, nasal, paterental or
rectal).
A pharmaceutical composition containing the compound as the active
ingredient can be formulated in conventional manner using one or more
physologically active carriers and excipients. Methods for making such
formulations can be found in manuals, e.g. "Remington Pharmaceutical
Sciences".
Influencing the process of sister chromatid separation may be also
beneficial in preventing birth defects caused by missegration of
chromosomes in human meioses. For example, since cases of human
aneuploidy such as Down's syndrome may be caused by premature
separation of sister chromatids (Griffin, 1996), the use of a drug that
inhibits
separase activity might be able to reduce precocious sister separation and
thereby the incidence of aneuploidy in human fetuses.
CA 02362794 2008-07-22
27855-94
22
Thus, in a further aspect, the invention relates to separase inhibitors for
the
prevention of birth defects caused by missegration of chromosomes in
human meioses.
Separase inhibitors may also be useful in applications which aim at the
deliberate polyploidisation of plant cells for crop development. In yeast, it
has been shown that inhibition of separase activity prevents chromosome
separation without blocking cell cycle progression and therefore gives rise
to cells with increased ploidy. Inhibitors that block separase's protease
activity could therefore be used to increase the ploidy of any eukaryotic
1o cell, including all plant cells. Increasing the ploidy of plant cells is
useful for
1) producing larger plants, 2) for increasing the ploidy of breeding stocks,
and 3) for generating fertile hybrids.
Therefore, the present invention relates, in a further aspect, to separase
inhibitors for the treatment of plant cells for increasing their ploidy.
To identify separase inhibitors that are useful for the above-mentioned
agricultural purposes, the screening method of the invention can be easily
adapted by employing plant components, i.e. a plant separase and a plant
homolog of SCC1. Sequence homologs of plant separase and SCC1 are
present in databases, e.g. of the Arabidopsis thaliana genome.
Separase inhibitors which impair sister chromatid separation may also be
used in cytological analyses of chromosomes, for example, in medical
diagnoses of chromosome structure.
In a further aspect the invention extends to a commercial
package containing an inhibitor for human .separase activity
and instructions for its use for human cancer therapy, or
for the prevention of birth defects caused by missegration
of chromosomes in meioses.
CA 02362794 2008-07-22
27855-94
23
Brief description of the figures:
Fig. 1: Chromosome association of Sccl p in G1 is Espl -dependent
Fig. 2: In vitro assay for Sccl p cleavage and dissociation from chromatin
Fig. 3: Detection of the Sccl p cleavage product in vivo in cells passing
sychronously throught the metaphase to anaphase transition
Fig. 4: Expression of a non-cleavable variant of Scc1 p prevents Sccl p
dissociation from chromosomes and sister chromatid separation in
vivo
Fig. 5: Purified Sccl is a substrate for the Esp1-dependent cleavage
reaction
Fig. 6: Mutations in the putative catalytic dyad of the Es p1 protease domain
abolish cleavage activity
Fig. 7: Separase cleavage of the cohesin Rec8 is necessary during meiotic
nuclear divisions
Fig. 8. Association of human SCC1 with chromatin
Fig. 9: Human SCC1 is cleaved in mitosis
Fig. 10: Ectopically expressed SCC1-myc is incorporated into the cohesin
complex and is cleaved in mitosis
Fig.1 1: Human SCC1 is not cleaved in human cells arrested in metaphase
by nocodazole treatment
Fig. 12: Human SCC1 is cleaved in anaphase
Fig. 13. Human SCC1-myc is cleaved in vitro
Fig. 14: Mapping of the N-terminal cleavage site of human SCC1
If not otherwise stated, the following materials and methods were used in
the'experiments of the present invention
CA 02362794 2001-08-14
WO 00/48627 PCT/EPO0/01183
24
a) Yeast plasmids and strains:
The Sccl p coding sequence (Saccharomyces Genome Database
YDLO03W) was cloned under control of the GAL 1-10 promoter in a
Ylplacl28 derived vector (Gietz and Sugino, 1988), and under its own
promoter into YCplacl 11 (Gietz and Sugino, 1988) using the polymerase
chain reaction (PCR). DNA fragments encoding multiple HA and myc
epitopes were inserted into restriction sites introduced by PCR at the N-
and C-termini of SCC1. Site directed mutagenesis was performed by PCR
using primers containing the desired nucleotide changes. The validity of all
1o constructs was verified by nucleotide sequencing.
All strains used were derivatives of W303 (HMLa HMRa ho ade2-1 trpl-1
canl-100 leu2-3,112 his3-11,15 ura3). Epitope tags at the endogenous
Sccl p were generated by a PCR one-step tagging method (Michaelis et al.,
1997). A strain overexpressing Espl p from the GAL 1-10 promoter was
described (Ciosk et al., 1998) and crossed to a strain containing the espl-1
mutation (McGrew et al., 1992). A strain expressing the sole source of
Cdc20p under control of the GAL 1-10 promoter was described in (Lim et
al., 1998). To visualize sister chromatids a Tet repressor-GFP fusion
protein is synthesized in the cells that binds to a cluster of Tet operator
sequences integrated at the URA3 locus close to the centromere of
chromosome V as described in (Michaelis et al., 1997).
All meiotic yeast strains used in Example 7 are derivatives of the rapidly
sporulating SK1. The Rec8 431/453 mutant (E428R R431 E R453E) was
generated by site-specific mutagenic PCR of a REC8 wild-type integrative
plasmid. This Ylplac128-derived plasmid (Gietz and Sugino, 1988)
contains the REC8 gene and promoter and 3 HA epitope sequences at the
C-terminus. This plasmid was integrated at the rec8::KanMX4 locus by
transformation with the Mlul-linearized plasmid.
The espl-2 allele (McGrew et al., 1992) was recovered from strain K8493
using a gap repair strategy as described by Guthrie and Fink, 1991. The
recovered allele was transferred into SK1 by transformation and 5-FOA
counter-selection (Guthrie and Fink, 1991). The resultant temperature-
sensitive strain was diploidized by transformation with plasmid cl743
containing the HO gene. For sporulation experiments, strains were first
CA 02362794 2001-08-14
WO 00/48627 PCT/EP00/01183
streaked from the -80 C stock onto a YEPGlycerol plate and grown for 60
hours at 25 C. A single colony was patched onto YEPD and grown for 48
hours at 25 C. The patch of cells was innoculated into liquid YEPD and
grown for 8 hours to stationary phase. The culture was washed with YEPA
5 and grown overnight in YEPA. Cells were washed with 2% Potassium
Acetate and then incubated for 14-24 hours in the same medium. Samples
were taken every two hours and fixed with 70% ethanol for visualizing
nuclei by DAPI staining.
b) Yeast cell growth and cell cycle experiments
10 Cells were grown in complete medium (Rose et al., 1990) at 25 C if not
otherwise stated. Strains expressing Cdc20p, Esp1 p, or Sccl p from the
GAL 1-10 promoter were grown in complete medium containing 2%
Raffinose as carbon source. The GAL 1-10 promoter was induced by
adding 2% galactose. A G1 like arrest was achieved by adding 1 pg/ml of
15 the pheromone alpha factor to the medium. For a metaphase arrest, 15
pg/ml nocodazole was added with 1 % DMSO. Metaphase arrest due to
Cdc20p depletion was obtained in cells with the sole source of Cdc20p
under control of the GAL 1-10 promoter. A logarithmically growing culture in
complete medium containing raffinose and galactose was filtered, washed
20 with medium containing Raffinose only, and resuspended in the same
medium. For release from the arrest 2% Galactose was added back to the
culture.
c) In vitro assay for yeast Esp1 p activity
A crude Triton X-100 insoluble chromatin preparation was obtained from
2 5 yeast cells as described (Liang and Stillman, 1997). The pelleted
chromatin
was resuspended in yeast cell extracts that had been prepared similar to
the supernatant fraction of the chromatin preparation. One tenth volume of
an ATP regenerating system was added (50 mM HEPES/KOH pH 7.5, 100
mM KCI, 10 mM MgC12, 10 mM ATP, 600 mM creatin phosphate, 1.5
mg/ml phophocreatin kinase, 1 mM DTT, 10% glycerol). Reactions were
incubated for 10 min at 25 C with shaking and stopped on ice. The
chromatin fraction was separated again from the supernatant by
centrifugation, and resuspended in buffer EBX (Liang and Stillman, 1997).
Equivalent aliquots of supernatant and chromatin pellet were analysed by
CA 02362794 2001-08-14
WO 00/48627 PCT/EP00/01183
26
SDS-PAGE and Western blotting. Sccl-HA was detected with the anti-HA
monoclonal antibody 16B12 (Boehringer Mannheim).
Since overexpression of Esp1 p from the GAL 1-10 promoter is toxic to cells,
extracts with overproduced Esp1 p were prepared 2 h after induction with
galactose of a culture pregrown in medium containing raffinose only.
d) Protein sequencing of the yeast Sccl p cleavage site
The C-terminal Sccl p cleavage fragment was isolated from cells that
contained Sccl p tagged with 18 tandem myc epitopes at the C-terminus. A
Cdc20 arrest/release strategy was employed to obtain cells containing a
1o high portion of Sccl p in the cleaved form. Protein extract of 5 x 109
cells
was prepared by breakage with glass beads 15 min after release from the
metaphase arrest. myc-epitope tagged protein was immunoprecipitated
with 20 mg anti-myc 9E11 monoclonal antibody under denaturing
conditions and resolved on SDS-PAGE next to size markers. Proteins were
transferred to a PVDF membrane and stained with Coomassie Brillant Blue
R250. N-terminal sequencing of the band corresponding to the Sccl p
cleavage fragment yielded the amino acid sequence RLGESIM
(Sccl p amino acids 269 onwards).
e) Purification of yeast Sccl expressed in baculovirus infected insect cells
2o The Sccl coding sequence was cloned into the baculovirus transfer vector
pFastBacl (Gibco Life Technologies). At the C-terminus a FLAG epitope
tag was added followed by a cassette containing the yeast VMA intein and
a chitin binding domain (New England Biolabs). Recombinant
baculoviruses were obtained following the manufacturer's instructions.
HiFive insect cells (Invitrogen) were grown in monolayers to confluency and
infected at an multiplicity of infection of 2 with the recombinant
baculovirus.
To obtain metaphase-like phosphorylation 0.1 ^M Okadaic acid was added
40 hours after infection. 43 hours after infection cells were harvested.
Cytoplasmic and nuclear extracts were obtained as described (Cai et al.,
1996). Sccl was purified from the combined extracts by chitin affinity
chromatography according to the manufacturer's protocols, and further
purified by two subsequent ion exchange chromatography steps on a
MonoQ column (Amersham Pharmacia).
CA 02362794 2001-08-14
WO 00/48627 PCT/EP00/01183
27
f) Mutations in the yeast Esp1 catalytic dyad
Esp1 was overexpressed as described in a). The conserved residues
histidine 1505 and cysteine 1531 that form the putative catalytic dyad of the
Esp1 protease were changed to alanine using a PCR based mutation
scheme. The mutant proteins were expressed from the GAL promoter in
yeast and assayed for there cleavage activity as described under c).
g) Other yeast methods
Analysis of DNA content was performed as described (Epstein and Cross,
1992) on a Becton Dickinson FACScan, chromosome spreads were as
1 o described (Michaelis et al., 1997), photo micrographs were taken with a
Photometrics CCD camera mounted on a Zeiss Axiophot microscope.
In vitro translation of Pdsl p was performed in reticulocyte lysate using the
TNT system (Promega).
h) Human cells
HeLa cells were cultivated in DMEM supplemented with 10% FCS at 37 C
and 5% C02.
In some experiments HeLa cells stably expressing mouse SCC1 fused to
9 myc ecpitopes at its C-terminus were used.
i) Human cell cycle experiments
2o For cell cycle synchronization, a double-thymidine treatment was used.
HeLa cells were first treated with 2 mM thymidine for 18 h. Subsequently,
cells were washed with PBS, fresh medium was added and the cells were
grown for another 8 h. Then the cells were treated again with 2 mM
thymidine for 18 h, subsequently washed and incubated in fresh medium.
Samples were taken at different time points. Samples were splitted and
used for FACscan analysis and for immunoblotting. Cell extracts were
made with glass-teflon potters in ice cold buffer containing 50 mM Tris pH
7.7, 100 mM NaCl, 20 mM b-glycerophosphate, 5 mM MgCI2, 1 mM NaF,
0.1-0.2% Triton X-100, 10% Glycerol, 1 mM DTT and protease inhibitors).
CA 02362794 2008-07-22
27855-94
28
In some experiments logarithmically growing HeLa cells were treated with
330 nM nocodazole dissolved in 0.1 % DMSO for 18 hours, or cells
synchronized by double-thymidine treatment were released into
nocodazole-containing medium for different periods of time. In control
experiments 0.1 % DMSO was added without nocodazole.
For SDS-PAGE, equal amounts of total extract was loaded (usually 50 ^g
protein per sample). For western blotting the following antibodies were
used: Monoclonal mouse-anti-separase a C-terminal fragment of human
separase was expressed in pET28Vector, His-tagged protein was purified
1o and used for immunization); rabbit-anti-SCC1 (N-terminal or C-terminal
peptides of human SCC1 were coupled to KLH and used for immunization);
rabbit anti-securin (human securin was expressed in pTrcHis2 vector,
His/myc-tagged protein was purified and used for immunization). All
antibodies were affinity purified. CDC27, CDC20 and proteasome
antibodies have been described (Gieffers et al., 1999). Mouse-anti-Cyclin
B1 (#SC-245) were from Santa Cruz Biotechnology, USA. Rabbit-anti-
Cyclin A (#06-138) and rabbit-anti -phopho-Histone H3 (#06-570) were
from Upstate Biotechnology, USA. Rabbit-anti-myc-epitope antibodies
(CM-100) were from Gramsch, Germany.
j) In vitro cleavage of SCC1-myc
Whole cell extract (containing 250 pg protein) from nocodazole-arrested
HeLa cells ectopically expressing mouse SCC1-myc was separated by
centrifugation into chromatin and supernatant fractions. Either 12.5 ul of the
supernatant fraction or the chromatin pellet (resuspended in 5 ul of buffer
containing 0.005 % Triton X100, 20 mM Hepes pH 7.7, 20 mM KCI, 1 mM
MgCI2, 2 mM CaCl2) were incubated with 25 pl of either interphase or
mitotic Xenopus egg extract at room temperature. At different time points
samples were taken, separated by SDS-PAGE and analyzed by
immunoblotting with anti-myc antibodies. Xenopus extracts were prepared
as described (Murray, 1991).
k) Mapping of the N-terminal cleavage site of human SCC1
For generating truncated versions of the human SCCI cDNA, polymerase
chain reactions (PCRs) were used. For N-terminal deletions different 5'-
CA 02362794 2001-08-14
WO 00/48627 PCT/EPOO/01183
29
primers containing T7 promotor regions, a start codon and appropriate
SCCI sequences were used. For C-terminal deletions different 3'-primers
with appropriate SCC1 sequences and a stop-codon were used. The
obtained PCR fragments were transribed and translated in the presence of
35S-methionine in reticulocyte lysate in vitro (TNT system, Promega). The in
vitro translated products were separated by SDS-PAGE and immunoblotted
with C- or N-terminal specific SCC1 antibodies.
Example I
1o Chromosome association of yeast Sccl p in G1 is Espl -dependent
A) Cells, wild type for ESPI or containing the espl-1 mutation, with an
unmodified endogenous copy of Sccl and a second myc-tagged copy
under the control of the GAL promoter were arrested with the mating
pheromone alpha factor for 120 min. All cells had then arrested in the G1
phase of the cell cycle (time point 0 of the experiment). The FACScan
profile of the DNA content is shown, demonstrating that all cells stayed
arrested during the following 120 min time course of the experiment.
Sccl myc was induced for 60 min by adding 2% galactose, then cells were
transferred to medium containing 2% glucose to repress Sccl myc
2o expression (Fig. 1A).
B) Expression of Sccl myc was seen by whole cell in situ hybridization
(open circles), and chromosome binding of Sccl myc was observed using
chromosome spreads (filled squares). The percentage of cells positive for
Sccl myc expression and that had Sccl myc bound to chromosomes is
shown in the graphs (Fig. 1B).
Example 2
In vitro assay for yeast Scc1 p cleavage and dissociation from chromatin
Chromatin was prepared from a strain containing Sccl p tagged with HA
epitopes that was arrested in metaphase with nocodazol. The proteins in
the chromatin preparation were resolved by SDS-PAGE and Sccl -HA was
detected by western blotting (Fig. 2, lane 1). This chromatin preparation
CA 02362794 2001-08-14
WO 00/48627 PCT/EPO0/01183
was resuspended in the indicated extracts, with or without addition of in
vitro translation products as indicated. Incubation was for 10 min at 25 C,
after which the chromatin was separated again from the supernatant by
centrifugation. Aliquots of the supernatant fraction and the chromatin
5 fraction of each reaction were analysed.
Example 3
Detection of the yeast Sccl p cleavage product in vivo in cells passing
sychronously throught the metaphase to anaphase transition
The strain used expressed Cdc20p under the control of the GAL promoter
1 o as the only source of Cdc20p. Sccl p was tagged with HA epitopes, and
sister chromatids were visualized by tetR-GFP bound to tetO sequences
inserted at the centromere of chromosome V. Cells were arrested at
metaphase by depleting the cells of Cdc20p in medium lacking galactose
for 120 min. Then 2% galactose was added to induce Cdc20p synthesis.
15 A) The FACscan profile of the time course is shown in Fig. 3A.
B) Budding (Fig. 3b, filled squares) was scored, all cells arrested after
120 min with large buds and cytokinesis happend for most cells between
30 min and 45 min after induction of Cdc20p synthesis. Sccl-HA bound to
chromosomes was seen on chromosome spreads (Fig. 3B, open circles) in
20 most cells in the arrest, and Sccl-HA disappeared from chromosomes
within 15 min after release. The percentage of cells with separated sister
chromatids as seen as the occurrence of two separated GFP dots in one
cell body is presented (Fig. 3B, filled triangles).
C) Examples of cells in the arrest at 120 min and 15 min after release. The
25 synchronous separation of sister chromatids is visible as separating GFP
dots (Fig. 3C).
D) Western blot analysis of whole cell extracts at the indicated time points.
The cleavage fragment of Sccl-HA is apparent at 135 min short after the
release from the metaphase block into anaphase (Fig. 3D).
30 Example 4
CA 02362794 2001-08-14
WO 00/48627 PCT/EP00/01183
31
Expression of a non-cleavable variant of yeast Sccl p prevents Sccl p
dissociation from chromosomes and sister chromatid separation in vivo
A) FACscan profile of the DNA content as unbudded G1 cells were
released into the cell cycle either with or without the induction of the
Scc1 RR-DD mutant (Fig. 4A).
B) Budding index without (Fig. 4B, open squares) or with (Fig. 4B, open
triangles) induction of Sccl RR-DD. Sister chromatid separation in the cells
was monitored by counting the percentage of cells containing two
separated GFP dots (Fig. 4B, filled squares for the control culture not
expressing Sccl RR-DD, and filled triangles for the culture expressing
Sccl RR-DD).
C) Sccl p chromosomse association was measured on chromosome
spreads. The endogenous wild type Sccl myc is shown for the control cells
(open squares) and cells expressing Scc1 RR-DD (Fig. 4c, open triangles).
The Sccl RR-DD was HA tagged and detected on chromosome spreads of
the induced culture (Fig. 4C, filled triangles).
D) Examples of chromosome spreads of both cultures at 150 min in
metaphase and at 180 min when most cells of the control culture had
undergone anaphase. The DNA was stained with DAPI, Sccl myc was
detected with a rabbit-anti-myc antiserum and anti-rabbit-Cy5 conjugated
secondary antibody, Sccl RR-DD-HA was detected with the mouse
monoclonal antibody 16B12 and anti-mouse-Cy3 conjugated secondary
antibody. Sister chromatids of centromere V were visualized by the GFP
dots (Fig. 4D).
Example 5
Purified yeast Sccl is a substrate for Esp1-dependent cleavage
Fig. 5A: Purification of Sccl from baculovirus-infected insect cells. SDS-
PAGE followed by staining with Coomassie brilliant blue R250 of control
HiFive whole cell extract (lane 1), whole cell extract after infection with
the
virus expressing Sccl (lane 2), the eluate from the chitin affinity column
(lane 3), and the pooled fraction of the second MonoQ chromatographic
CA 02362794 2001-08-14
WO 00/48627 PCT/EP00/01183
32
step (lane 4). Sccl, purified in a similar way, but containing metaphase-like
phosphorylation, is shown in lane 5.
Fig. 5B: Cleavage assay using purified Sccl. Purified Sccl in both the
unphosphorylated and the metaphase-like phosphorylated form was used
as a substrate in a cleavage assay. The cell extract containing Esp1 was
as in Figure 2, but was used mixed in different ratios with the control
extract
to obtain a titration of the Esp1 activity. Sccl was detected by Western
blotting with the anti-FLAG monoclonal antibody M2 (Sigma).
Example 6
1o Mutation of the catalytic dyad in yeast Esp1 abolishes its cleavage
activity.
Wildtype Esp1 and mutants H1505A and C1531A were overexpressed in
yeast, tagged with a FLAG epitope for detection. Fig 6A: Western blot of
cell extracts showing that the two mutant Esp1 proteins were expressed as
stable proteins to similar levels as the wild type protein. Fig. 6B: The
associated Sccl cleavage activity was assayed as in Example 2.
Example 7
Preventing cleavage of the meiotic cohesion protein Rec8 by mutations in
its cleavage sites or by an esp1 mutation inhibits meiotic nuclear divisions
Fig. 7A: Diploid yeast strains either wild type for Rec8 or expressing Rec8
with both cleavage sites mutated were sporulated. The percentage of cells
containing either one nucleus, two nuclei, or three or four nuclei is depicted
throughout the time course of the experiment.
Fig. 7B: A diploid yeast strain homozygous for the espl -2 mutation was
sporulated at 25 C or 35 C. The percentage of cells containing either one
nucleus, two nuclei, or three or four nuclei is depicted.
Example 8
Association of human SCC1 with chromatin
Chromatin and supernatant fractions were prepared from HeLa cells that
were either growing logarithmically (log) or were arrested in metaphase
with nocodazole (noc). Proteins from equivalent aliquots of these fractions
CA 02362794 2001-08-14
WO 00/48627 PCT/EP00/01183
33
were separated by SDS-PAGE and analyzed for the presence of SCC1 by
immunoblotting using radiolabeled antibodies (Fig. 8, top panel), The
intensities of the SCC1 bands were quantitated (Fig. 8, bottom panel).
Example 9
Human SCC1 is cleaved in mitosis
HeLa cells were arrested at the onset of S-Phase by a double-thymidine
treatment and were synchronously released into the cell cycle. Samples
were taken at the indicated time points. Cells were analyzed for their DNA
content by.FACscan (Fig. 9A) and by SDS-PAGE and immunoblotting of
whole cell extracts using the indicated antibodies (Fig. 9B). The
phosphorylation-dependent electrophoretic mobility shift of the APC subunit
CDC27 was used as a marker for mitotic entry. The disapperance of
cyclin A was used as a marker for metaphase, and the disappearance of
CDC20, securin and cyclin B as a marker for anaphase. Proteasome levels
were determined as a loading control. The arrows in panels 3 and 4 of Fig.
9B from the top indicate 100 and 25 kDa bands that are recognized by
antibodies that are specific for the C- and the N-terminus of SCC1,
respectively.
Example 10
Ectopically expressed SCC1-myc is incorporated into the cohesin complex
and is cleaved in mitosis
Fig. 10A: An extract of logarithmically growing HeLa cells stably expressing
SCC1-myc was separated by 5-20% sucrose density gradient
centrifugation. Proteins from each gradient fraction were analyzed by SDS-
PAGE and immunoblotting using antibodies to SCC1, the myc epitope and
against the human cohesin subunit SA1. The position of 9S and 14S
cohesin complexes is indicated. Both endogenous SCC1 and ectopically
expressed SCC1-myc are exclusively found in the fractions containing the
14S cohesin complex.
Fig. 10B: HeLa cells stably expressing SCCI -myc were arrested by double-
thymidine treatment and synchronously released into the cell cycle.
Samples were taken at the indicated time points and whole cell extracts
CA 02362794 2001-08-14
WO 00/48627 PCT/EP00/01183
34
were analyzed by SDS-PAGE and immunoblotting using antibodies agaist
the myc epitope and the C-terminus of SCC1. SCC1 cleavage products are
indicated by arrows. Two exposures of the myc immunoblot are shown to
reveal a second SCC1-myc cleavage product of higher electrophoretic
mobility that can only be detected in prolonged exposures (bottom panel).
Example 11
Human SCC1 is not cleaved in human cells arrested in metaphase by
nocodazole treatment
HeLa cells stably expressing SCC1-myc were synchronized by double-
1o thymidine treatment and were released into the cell cycle in the presence
of
either DMSO (results shown in Fig. 11A and C) or nocodazole dissolved in
DMSO (results shown in Fig. 11 B and D). At indicated time points samples
were taken. Cells were analyzed by FACsan (Fig. 11A and B) and by
immunoblotting of whole cell extracts using the indicated antibodies
(Fig. 11 C and D). Antibodies specific for the C-terminus of SCC1 were
used. In addition to the antibodies used in Example 9, an antibody specific
for mitotically phosphorylated histone H3 (PhosphoH3) was used as a
mitotic marker.
Example 12
SCC1 is cleaved in anaphase
HeLa cells stably expressing SCC1-myc were arrested in metaphase with
nocodazole and synchronously released into anaphase. Samples were
taken at the indicated time points. Cells were analyzed by FACscan
(Fig. 12A) and by immunoblotting of whole cell extracts using the indicated
antibodies (Fig. 12B). Antibodies specific for the C-terminus of SCC1 were
used.
Example 13
SCC1-myc is cleaved in vitro
Chromatin and supernatant fractions were isolated by differential
centrifugation from nocodazole-arrested HeLa cells stably expressing
SCC1-myc. The chromatin fraction was incubated in mitotic and interphase
CA 02362794 2001-08-14
WO 00/48627 PCT/EP00/01183
Xenopus egg extracts and the supernatant fraction in mitotic Xenopus egg
extract. Samples were taken at the time points indicated in Fig. 13 and
analyzed by SDS-PAGE and immunoblotting using antibodies to the myc
epitope. Whole cell extracts from SCCI-myc expressing HeLa cells in
5 S-phase or in anaphase (obtained by release from a double-thymidine
arrest for 6 and 11.5 hours, respectively) were analyzed side by side.
Cleavage products of SCC1-myc that are specifically formed in mitotic
Xenopus extrcats are indicated by arrows.
Example 14
10 Mapping of the N-terminal cleavage site of human SCC1
Truncated versions of the human SCC1 cDNA were generated by PCR and
transcribed and translated in vitro. The 35S-labeled in vitro translation
products (35S-IVT) were analyzed by immunoblotting with SCC1 antibodies
(top panels) and by phosphorimaging (bottom panels). N-terminal deletion
15 mutants were analyzed by immunoblotting with antibodies specific for the
C-terminus of SCCI (Fig. 14, left panels) and C-terminal deletion mutants
were analyzed with antibodies specific for the N-terminus of SCC1 (Fig. 14,
right panels). Extracts from SCC1-myc expressing HeLa cells in anaphase
or in G1 (obtained by release from a double-thymidine arrest) were
2o analyzed side by side. The SCC1 cleavage products detected in HeLa
extracts are indicated by arrows.
CA 02362794 2001-08-14
WO 00/48627 PCT/EP00/01183
36
References
Ambrose WP, et al., (1998), Anal Biochem, Oct 15, 263(2): 150-7
Brown AM, et al., (1994), Anal Biochem, Feb 15, 217(1): 139-47
Cai J, et al., (1996): Reconstitution of human replication factor C from its
five subunits in baculovirus-infected insect cells. Proc. Natl. Acad. Sci. USA
93, 12896-12901
Cerretani M, et al., (1999), Anal Biochem, Jan 15, 266(2): 192-7
Ciosk R, Zachariae W, Michaelis C, Shevchenko A, Mann M, and Nasmyth
K (1998): An ESP1/PDS1 complex regulates loss of sister chromatid
cohesion at the metaphase to anaphase transition in yeast. Cell 93, 1067-
1076
Cohen-Fix 0, Peters J-M, Kirschner MW, and Koshland D (1996):
Anaphase initiation is Sacharomyces cervisiae is controlled by the APC-
dependent degradation of the anaphase inhibitor Pdsl p. Genes Dev 10,
3081-3093
Dougherty WG, Cary SM and Dawn Parks T (1989): Molecular Genetic
Analysis of a Plant Virus Polyprotein Cleavage Site: A Model. Virology 171,
356-364
2o Dominguez A, Ramos-Morales F, Romero F, Rios RM, Dreyfus F, Tortolero
M and Pintor-Toro JA (1998): hpttg, a human homologue of rat pttg, is
overexpressed in hematopoietic neoplasms. Evidence for a transcrptional
activation function of hPTTG. Oncogene 17: 2187-2193
Epstein CB, and Cross FR (1992) CLB5: a novel cyclin from budding yeast
with a role in S-phase. Genes Dev. 6, 1695-1706
Faleiro L, Kobayashi R, Fearnhead H, and Lazebnik Y (1997): Multiple
species of CPP32 and Mch2 are the major active caspases present in
apoptotic cells. EMBO J. 16, 2271-2281
CA 02362794 2001-08-14
WO 00/48627 PCT/EP00/01183
37
Funabiki H, et al., (1996): Cut2 proteolysis required for sister-chromatid
separation in fission yeast. Nature 381, 438-441
Gershkovich, A.A. and Kholodovych, V.V. (1996), J Biochem Biophys Meth
33, 135
Gietz RD and Sugino A (1988): New yeast-Escherichia coli shuttle vectors
constructed with in vitro mutagenized yeast genes lacking six-base pair
restriction sites. Gene 74, 527-534
Gray NM, et al., (1994), Anal Biochem, 216(1): 89-96
Guthrie, C. and Fink, G.R, editors (1991): Guide to Yeast Genetics and
Molecular Biology, Methods in Enzymology, Volume 194, Academic Press,
Inc., USA
Hayden JH, Bowser SS, and Rieder CL (1990): Kinetochores capture astral
microtubules during chromosome attachment to the mitotic spindle: direct
visualization in live newt lung cells. J. Cell Biol. 3, 1039-1045
Jolley, M.E. (1996), J Biomol Screening 1, 33
Kramer ER, Gieffers C, HOIzI G, Hengstschlager M and Peters JM (1998):
Activation of the human anaphase-promoting complex by proteins of the
CDC10/Fizzy family. Current Biology 8: 1207-1210
Kerrebrock AW, Moore DP, Wu JS, and Orr-Weaver TL (1995): Mei-S332,
2o a Drosophila protein required for sister chromatid cohesion, can localize
to
meiotic centromere regions. Cell 83, 247-256
Klein F, et al., (1999): A central role for the cohesins in sister chromatid
cohesion , formation of axial elements, and recombination during yeast
meiosis. Cell 98, 91-103
Levine LM, et al., (1997), Anal Biochem, Apr 5, 247(1): 83-8
Liang C, and Stillman B (1997): Persistent initiation of DNA replication and
chromatin-bound MCM proteins during the cell cycle in cdc6 mutants.
Genes Dev 11, 3375-3386
CA 02362794 2001-08-14
WO 00/48627 PCT/EP00/01183
38
Lim HH, Goh P-Y, and Surana U (1998): Cdc20 is essential for the
cyclosome-mediated proteolysis of both Pdsl and CIb2 during M phase in
budding yeast. Curr. Biol. 8, 231-234
Losada A, Hirano M, and Hirano T (1998): Identification of Xenopus SMC
protein complexes required for sister chromatid cohesion. Genes Dev 12,
1003-1012
Matayoshi, E.D. (1990), Science 247, 954
McKay MJ, et al., (1996): Sequence conservation of the rad2l
Schizosaccharomyces pompe DNA double-strand break repair gene in
human and mouse. Genomics 36, 305-315
McGrew JT, Goetsch L, Byers B, and Baum P (1992): Requirement for
ESP1 in the nuclear division of S. cerevisiae. Mol. Biol. Cell 3, 1443-1454
Merdes A, and De Mey J (1990): The mechanism of kinetochore-spindle
attachment and polewards movement analyzed in PtK2 cells at the
prophase-prometaphase transition. Eur. J. Cell Biol. 53, 313-325
Michaelis C, Ciosk R, and Nasmyth K (1997): Cohesins: Chromosomal
proteins that prevent premature separation of sister chromatids. Cell 91,
35-45
Miyazaki WY, and Orr-Weaver TL (1994): Sister chromatid cohesion in
mitosis and meiosis. Annu. Rev. Genet. 28, 167-187
Moore DP, Page AW, Tang TTL, Kerrebrock AW, and Orr-Weaver TL
(1998): The cohesion protein Mei-S322 localizes to condensed meiotic and
mitotic centromeres until sister chromatids separate. J. Cell Biol. 140,
1003-1012
Murray AW (1991): Cell cycle extracts. Methods In cell biology 36, 581-605
Murray MG, et al., (1993), Gene, Nov 30, 134(1):123-8
Nagase T, Seki N, Ishikawa K, Tanaka A, and Nomura N (1996): Prediction
of the coding sequences of unidentified human genes. V. The coding
CA 02362794 2001-08-14
WO 00/48627 PCT/EP00/01183
39
sequences of 40 new genes (KIAAO 161 -KIAA0200) deduced by analysis of
cDNA clones from human cell line KG-1. DNA Res 3, 17-24
Nicholson DW, et al., (1995): Identification and inhibition of the ICE/CED-3
protease necessary for mammalian apoptosis. Nature 376, 37-43
Peters J-M (1998): SCF and APC the Yin and Yan of cell cycle regulated
proteolysis. Curr. Op. Cell Biol. 10, 759-768
Remington's Pharmacuetical Sciences, 1980, Mack Publ. Co. Easton, PA,
Osol (ed.)
Rieder CL, and Salmon ED (1998): The vertebrate cell kinetochore and its
roles during mitosis. Trends Cell. Biol. 8, 310-318
Rose MD, Winston F, and Hieter P (1990): Laboratory course manual for
methods in Yeast Genetics (Cold Spring Harbor Laboratory Press, Cold
Spring Harbor, New York)
Sarubbi E, et al., (1991), FEBS Lett, Feb 25, 279(2): 265-9
Singh J, et al., (1996), Bioorg Med Chem, 4(5): 639-43
Stebbins J. and Debouck C., (1997), Anal Biochem, Jun 1, 248(2): 246-50
Taliani M, et al., (1996), Anal Biochem, Aug 15, 240(1):60-7
Uhlmann F, and Nasmyth K (1998): Cohesion between sister chromatids
must be established during DNA replication. Curr. Biol. 8, 1095-1101
Zou H, McGerry TJ, Bernal T, Kirschner MW (1999): Identification of a
vertebrate sister-chromatid separation inhibitor involved in transformation
and tumorigenesis. Science 285:418-422
CA 02362794 2010-02-03
27855-94
SEQUENCE LISTING
<110> Boehringer Ingelheim International GmbH
<120> Compounds modulating sister chromatid separation and
methods for identifying same
<130> 14047peptide
<140>
<141>
<160> 1
<170> Patentln Ver. 2.1
<210> 1
<211> 18
<212> PRT
<213> Homo sapiens
<400> 1
Met Asp Asp Arg Glu Ile Met Arg Glu Gly Ser Ala Phe Glu Asp Asp
1 5 10 15
Asp Met
